Shares of Accuray ARAY rose 1.66% in after-market trading after the company reported Q4 results.
Earnings per share rose 100.00% year over year to ($0.00), which beat the estimate of ($0.02).
Revenue of $94,977,000 decreased by 19.11% from the same period last year, which beat the estimate of $91,560,000.
Accuray hasn't issued any earnings guidance for the time being.
Revenue guidance hasn't been issued by the company for now.
Conference Call Details
Date: Aug 13, 2020
Time: 04:30 PM
ET Webcast URL: https://www.webcaster4.com/Webcast/Page/2330/35923
52-week high: $4.68
52-week low: $1.33
Price action over last quarter: Up 12.71%
Accuray Inc is a radiation oncology company that develops, manufactures, sells and supports precise, innovative treatment solutions which set the standard of radiation therapy care with the aim of helping patients live better lives. The company's technology, The CyberKnife, is used to treat multiple types of cancer and tumors throughout the body. The CyberKnife Systems automatically track, detect and correct for a tumor and patient movement in real-time during the procedure, enabling delivery of precise, high dose radiation with sub-millimetre accuracy while patients breathe normally, without manual user intervention. CyberKnife Systems requires no anesthesia, and treatment sessions are done on an outpatient basis.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.